文献速递流行病学与生物统计临床试验与 GCP

32种口服与长效注射抗精神病药维持治疗成人精神分裂症疗效与耐受性比较:系统综述与网状Meta分析

Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis.
PubMed 文献 · Lancet · 2022-01-01

该系统综述与网状Meta分析纳入127项随机对照试验(共18152例非难治性成人精神分裂症或分裂情感性障碍患者),比较32种抗精神病药维持治疗预防复发的疗效与耐受性。所有药物对比安慰剂的复发风险比均小于1.00,但药物间多数比较无明确差异,作者结论为选择抗精神病药主要应依据耐受性。

要点

  • 所有抗精神病药对比安慰剂的复发风险比均小于1.00,几乎所有药物的95%可信区间排除无效应。
  • 复发风险比从帕利哌酮口服的0.20(95% CrI 0.05-0.41)到卡利拉嗪口服的0.65(0.16-1.14),证据置信度为中至低。
  • 多数抗精神病药之间的比较包含无差异的概率,未发现特定药物在预防复发方面有明确优势。

核心结论

  • 作者认为,由于未发现抗精神病药之间在预防复发方面有明确差异,维持治疗药物的选择主要应依据耐受性。

研究设计与样本

  • 系统综述与网状Meta分析,检索Cochrane精神分裂症组专业注册库(建库至2020年4月27日)、PubMed(2020年4月1日至2021年1月15日)及相关系统综述的纳入研究列表,无语言限制。
  • 纳入随访至少12周的随机对照试验,对象为症状稳定的成人精神分裂症或分裂情感性障碍患者,接受抗精神病药单药(口服或长效注射)或安慰剂治疗。
  • 排除特定共病患者或治疗抵抗患者的随机对照试验;由两名作者独立筛选文献并提取汇总数据。
  • 共纳入127项随机对照试验、32种抗精神病药、18152例参与者;主要结局(复发人数)的网状Meta分析纳入100项研究、16812例参与者、30种抗精神病药。
  • 主要结局采用随机效应贝叶斯网状Meta分析;研究注册于PROSPERO,CRD42016049022。

主要发现

  • 所有抗精神病药对比安慰剂预防复发的风险比均小于1.00,几乎所有药物的95%可信区间排除无效应。
  • 复发风险比范围为帕利哌酮口服的0.20(95% CrI 0.05-0.41)至卡利拉嗪口服的0.65(0.16-1.14),证据置信度为中至低。
  • 多数抗精神病药之间的比较包含无差异的概率,未发现特定药物在预防复发方面有明确优势的清晰证据。

临床怎么用

  • 作者结论认为,由于未发现抗精神病药之间在预防复发方面有明确差异,维持治疗药物的选择主要应依据耐受性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Schizophrenia is a common, severe, and usually chronic disorder. Maintenance treatment with antipsychotic drugs can prevent relapse but also causes side-effects. We aimed to compare the efficacy and tolerability of antipsychotics as maintenance treatment for non-treatment resistant patients with schizophrenia. METHODS: In this systematic review and network meta-analysis, we searched, without language restrictions, the Cochrane Schizophrenia Group's specialised register between database inception and April 27, 2020, PubMed from April 1, 2020, to Jan 15, 2021, and the lists of included studies from related systematic reviews. We included randomised controlled trials (RCTs; ≥12 weeks of follow-up) that recruited adult participants with schizophrenia or schizoaffective disorder with stable symptoms who were treated with antipsychotics (monotherapy; oral or long-acting injectable) or placebo. We excluded RCTs of participants with specific comorbidities or treatment resistance. In duplicate, two authors independently selected eligible RCTs and extracted aggregate data. The primary outcome was the number of participants who relapsed and was analysed by random-effects, Bayesian network meta-analyses. The study was registered on PROSPERO, CRD42016049022. FINDINGS: We identified 4157 references through our search, from which 501 references on 127 RCTs of 32 antipsychotics (comprising 18 152 participants) were included. 100 studies including 16 812 participants and 30 antipsychotics contributed to our network meta-analysis of the primary outcome. All antipsychotics had risk ratios (RRs) less than 1·00 when compared with placebo for relapse prevention and almost all had 95% credible intervals (CrIs) excluding no effect. RRs ranged from 0·20 (95% CrI 0·05-0·41) for paliperidone oral to 0·65 (0·16-1·14) for cariprazine oral (moderate-to-low confidence in estimates). Generally, we interpret that there was no clear evidence for the superiority of specific antipsychotics in terms of relapse prevention because most comparisons between antipsychotics included a probability of no difference. INTERPRETATION: As we found no clear differences between antipsychotics for relapse prevention, we conclude that the choice of antipsychotic for maintenance treatment should be guided mainly by their tolerability. FUNDING: The German Ministry of Education and Research and Oxford Health Biomedical Research Centre.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Schneider-Thoma J, Chalkou K, Dörries C, et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet. 2022. PMID: 35219395. doi:10.1016/S0140-6736(21)01997-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。